<PAGE>   1
 
================================================================================
                       SECURITIES AND EXCHANGE COMMISSION

                            WASHINGTON, D. C. 20549


                                   FORM 10-Q


          [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
                            SECURITIES EXCHANGE ACT OF 1934

                  FOR THE QUARTERLY PERIOD ENDED JUNE 30, 1997

                                       OR

          [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
                        SECURITIES EXCHANGE ACT OF 1934

           FOR THE TRANSITION PERIOD FROM  __________ TO  __________
 
                         COMMISSION FILE NUMBER 0-28434
 
                            ------------------------
 
                                 DIATIDE, INC.
--------------------------------------------------------------------------------
             (EXACT NAME OF REGISTRANT AS SPECIFIED IN ITS CHARTER)
 
<TABLE>
<S>                                           <C>
                   DELAWARE                                     04-3078258
--------------------------------------------------------------------------------------------
        STATE OR OTHER JURISDICTION OF                        (IRS EMPLOYER
        INCORPORATION OR ORGANIZATION)                     IDENTIFICATION NO.)
 
      NINE DELTA DRIVE, LONDONDERRY, NH                           03053
--------------------------------------------------------------------------------------------
   (ADDRESS OF PRINCIPAL EXECUTIVE OFFICES)                     (ZIP CODE)
</TABLE>
 
                                  603-437-8970
--------------------------------------------------------------------------------
              (REGISTRANT'S TELEPHONE NUMBER, INCLUDING AREA CODE)
 
     INDICATE BY CHECK MARK WHETHER THE REGISTRANT (1) HAS FILED ALL REPORTS TO
BE FILED BY SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 DURING
THE PRECEDING 12 MONTHS (OR FOR SUCH SHORTER PERIOD THAT THE REGISTRANT WAS
REQUIRED TO FILE SUCH REPORTS), AND (2) HAS BEEN SUBJECT TO SUCH FILING
REQUIREMENTS FOR THE PAST 90 DAYS.
                              YES   X          NO
                                  -----           -----

     THE NUMBER OF SHARES OUTSTANDING OF THE REGISTRANT'S COMMON STOCK, $0.001
PAR VALUE, AS OF AUGUST 8, 1997 WAS 10,515,293.
================================================================================
<PAGE>   2
 
                                 DIATIDE, INC.
 
                               TABLE OF CONTENTS
 
<TABLE>
<CAPTION>
                                                                                  PAGE NO.
                                                                                  --------
<S>        <C>                                                                    <C>
PART I  FINANCIAL INFORMATION

  ITEM 1   Financial Statements (Unaudited)
 
           Condensed Balance Sheets as of June 30, 1997 and December 31, 1996...      3

           Condensed Statements of Operations for the three months ended June
             30, 1997 and 1996..................................................      4

           Condensed Statements of Operations for the six months ended June 30,
             1997 and 1996, and for the period from February 6, 1990 (date of
             inception) to June 30, 1997........................................      5

           Condensed Statements of Cash Flows for the six months ended June 30,
             1997 and 1996, and for the period from February 6, 1990 (date of
             inception) to June 30, 1997........................................      6

           Notes to Condensed Financial Statements..............................      7

  ITEM 2   Management's Discussion and Analysis of Financial Condition and
             Results of Operations..............................................      8

PART II  OTHER INFORMATION

  ITEM 4   Submission of Matters to a Vote of Security Holders..................     11

  ITEM 6   Exhibits and Reports on Form 8-K.....................................     11

SIGNATURES......................................................................     12
</TABLE>
 
                                        2
<PAGE>   3
 
                         PART I.  FINANCIAL INFORMATION
 
ITEM 1.  FINANCIAL STATEMENTS
 
                                 DIATIDE, INC.
                         (A DEVELOPMENT STAGE COMPANY)
 
                            CONDENSED BALANCE SHEETS
 
<TABLE>
<CAPTION>
                                                                                   
                                                                                   
                                                                    JUNE 30,        DECEMBER 31,
                                                                      1997              1996
                                                                  -------------     ------------
                                                                   (UNAUDITED)
<S>                                                               <C>               <C>
ASSETS
Current assets:
  Cash and cash equivalents.....................................   $  2,698,034     $  6,004,207
  Marketable securities.........................................      7,778,202       10,782,632
  Other current assets..........................................        289,161          443,776
                                                                   ------------     ------------
Total current assets............................................     10,765,397       17,230,615
Property and equipment, at cost.................................      2,514,395        2,373,540
Less: accumulated depreciation and amortization.................      1,528,064        1,300,051
                                                                   ------------     ------------
                                                                        986,331        1,073,489
Other assets....................................................         10,783           10,783
                                                                   ------------     ------------
Total assets....................................................   $ 11,762,511     $ 18,314,887
                                                                   ============     ============
LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities:
  Accounts payable and accrued expenses.........................   $    980,168     $  1,514,905
  Accrued clinical expenses.....................................      1,794,603        2,099,826
  Current portion of capital lease obligation...................          3,460            3,460
                                                                   ------------     ------------
Total current liabilities.......................................      2,778,231        3,618,191
Capital lease obligation, less current portion..................         11,455           12,878
Stockholders' equity:
  Preferred stock, $0.01 par value 
  Authorized shares -- 10,591,874 
  Issued and outstanding shares -- none.........................             --               --
  Common stock, $0.001 par value
  Authorized shares -- 50,000,000
     Issued shares -- 10,520,094 (10,404,248 in 1996)...........         10,520           10,404
  Additional paid-in capital....................................     50,327,617       50,140,186
  Deferred compensation.........................................     (1,119,254)      (1,285,483)
  Deficit accumulated during development stage..................    (40,246,034)     (34,181,265)
                                                                   ------------     ------------
                                                                      8,972,849       14,683,842
  Less: 4,800 shares of common stock in treasury, at cost.......            (24)             (24)
                                                                   ------------     ------------
Total stockholders' equity......................................      8,972,825       14,683,818
                                                                   ------------     ------------
Total liabilities and stockholders' equity......................   $ 11,762,511     $ 18,314,887
                                                                   ============     ============
</TABLE>
 
---------------
 
Note: The balance sheet at December 31, 1996 has been derived from audited
      financial statements at that date but does not include all of the
      financial information and footnotes required by generally accepted
      accounting principles for complete financial statements.
 
                  See Notes to Condensed Financial Statements.
 
                                        3
<PAGE>   4
 
                                 DIATIDE, INC.
                         (A DEVELOPMENT STAGE COMPANY)
 
                       CONDENSED STATEMENTS OF OPERATIONS
                                  (UNAUDITED)
 
<TABLE>
<CAPTION>
                                                                   THREE MONTHS ENDED JUNE 30,
                                                                  -----------------------------
                                                                     1997              1996
                                                                  -----------       -----------
<S>                                                               <C>               <C>
Revenues:
  Sponsored research............................................  $   500,000       $   500,000
  License fees..................................................           --           500,000
  Research grants...............................................       30,000            56,073
                                                                  -----------       -----------
Total revenues..................................................      530,000         1,056,073
Costs and expenses:
  Research and development......................................    3,219,125         3,663,644
  General and administrative....................................      862,302           584,588
                                                                  -----------       -----------
Total costs and expenses........................................    4,081,427         4,248,232
Loss from operations............................................   (3,551,427)       (3,192,159)
Other income (expense):
  Interest income...............................................      182,423           108,368
  Interest expense..............................................         (452)           (6,142)
                                                                  -----------       -----------
Total other income (expense)....................................      181,971           102,226
                                                                  -----------       -----------
Net loss........................................................  $(3,369,456)      $(3,089,933)
                                                                  ===========       ===========
Net loss and pro forma net loss per share (Note 4)..............  $     (0.32)      $     (0.37)
                                                                  ===========       ===========
Shares used in computing net loss and pro forma net loss per
  share (Note 4)................................................   10,478,043         8,464,612
</TABLE>
 
                  See Notes to Condensed Financial Statements.
 
                                        4
<PAGE>   5
 
                                 DIATIDE, INC.
                         (A DEVELOPMENT STAGE COMPANY)
                       CONDENSED STATEMENTS OF OPERATIONS
                                  (UNAUDITED)
 
<TABLE>
<CAPTION>
                                                                                      FOR THE PERIOD
                                                                                     FEBRUARY 6, 1990
                                                   SIX MONTHS ENDED JUNE 30,       (DATE OF INCEPTION)
                                                -------------------------------        TO JUNE 30,
                                                   1997                1996                1997
                                                -----------         -----------    --------------------
<S>                                             <C>                 <C>            <C>
Revenues:
  Sponsored research........................... $ 1,000,000         $ 1,000,000        $  3,778,388
  License fees.................................          --             500,000           1,300,000
  Research grants..............................     110,000              56,073             665,498
                                                -----------         -----------        ------------
Total revenues.................................   1,110,000           1,556,073           5,743,886
Costs and expenses:
  Research and development.....................   5,990,007           6,192,247          37,377,319
  General and administrative...................   1,581,443           1,023,600          10,205,130
                                                -----------         -----------        ------------
Total costs and expenses.......................   7,571,450           7,215,847          47,582,449
Loss from operations...........................  (6,461,450)         (5,659,774)        (41,838,563)
Other income (expense):
  Interest income..............................     397,638             224,757           1,834,138
  Interest expense.............................        (957)            (16,176)           (241,609)
                                                -----------         -----------        ------------
Total other income (expense)...................     396,681             208,581           1,592,529
                                                -----------         -----------        ------------
Net loss....................................... $(6,064,769)        $(5,451,193)       $(40,246,034)
                                                ===========         ===========        ============
Net loss and pro forma net loss per share (Note
  4)........................................... $     (0.58)        $     (0.65)
                                                ===========         ===========
Shares used in computing net loss and pro forma
  net loss per share (Note 4)..................  10,455,377           8,330,108
</TABLE>
 
                  See Notes to Condensed Financial Statements.
 
                                        5
<PAGE>   6
 
                                 DIATIDE, INC.
                         (A DEVELOPMENT STAGE COMPANY)
 
                       CONDENSED STATEMENTS OF CASH FLOWS
                                  (UNAUDITED)
 
<TABLE>
<CAPTION>
                                                                                     FOR THE PERIOD
                                                                                    FEBRUARY 6, 1990
                                                    SIX MONTHS ENDED JUNE 30,      (DATE OF INCEPTION)
                                                   ---------------------------         TO JUNE 30,
                                                      1997            1996                1997
                                                   -----------     -----------     -------------------
<S>                                                <C>             <C>             <C>
OPERATING ACTIVITIES:
Net loss.........................................  $(6,064,769)    $(5,451,193)       $ (40,246,034)
Adjustments to reconcile net loss to cash used in
  operating activities:
  Depreciation and amortization..................      228,013         196,897            1,566,919
  Cancellation of accrued interest...............           --              --              111,438
  Amortization of deferred compensation..........      166,229         167,287              543,746
  Compensation associated with stock option
     grants......................................       89,924              --              165,884
  Changes in operating assets and liabilities....     (685,345)      1,766,370            2,435,972
                                                   -----------     -----------        -------------
     Cash used in operating activities...........   (6,265,948)     (3,320,639)         (35,422,075)
INVESTING ACTIVITIES:
Additions to property and equipment..............     (140,855)       (322,866)          (2,495,037)
Purchases of marketable securities...............   (3,995,570)     (1,351,749)         (20,623,296)
Sales and maturities of marketable securities....    7,000,000       4,910,094           12,845,094
                                                   -----------     -----------        -------------
     Cash provided by (used in) investing
       activities................................    2,863,575       3,235,479          (10,273,239)
FINANCING ACTIVITIES:
Sale of preferred stock..........................           --              --           28,255,133
Issuance of convertible notes....................           --              --            3,508,464
Repayment of convertible notes...................           --              --             (315,000)
Issuance of long-term debt.......................           --              --              900,518
Repayment of long-term obligations...............       (1,423)       (107,050)            (904,961)
Sale of common stock.............................       97,623      16,641,958           16,949,218
Repurchase of common stock.......................           --              --                  (24)
Capitalized financing costs......................           --              --                   --
                                                   -----------     -----------        -------------
     Cash provided by (used in) financing
       activities................................       96,200      16,534,908           48,393,348
                                                   -----------     -----------        -------------
Net (decrease) increase in cash and cash
  equivalents....................................   (3,306,173)     16,449,748            2,698,034
Cash and cash equivalents at beginning of
  period.........................................    6,004,207       5,084,197                   --
                                                   -----------     -----------        -------------
Cash and cash equivalents at end of period.......  $ 2,698,034     $21,533,945        $   2,698,034
                                                   ===========     ===========        =============
Noncash transactions:
  Acquisition of equipment through capital lease
     obligation..................................  $        --     $        --        $      19,358
  Conversion of convertible notes and accrued
     interest to preferred stock.................  $        --     $        --        $   3,304,902
  Deferred compensation associated with stock
     options issued at less than fair value......  $        --     $        --        $   1,663,000
  Conversion of preferred stock to common
     stock.......................................  $        --     $31,559,922        $  31,559,922
</TABLE>
 
                  See Notes to Condensed Financial Statements.
 
                                        6
<PAGE>   7
 
                                 DIATIDE, INC.
                         (A DEVELOPMENT STAGE COMPANY)
 
                    NOTES TO CONDENSED FINANCIAL STATEMENTS
                                  (UNAUDITED)
 
1.  NATURE OF BUSINESS
 
     Diatide, Inc. (the "Company") was founded in 1990 and is a development
stage biopharmaceutical company engaged in the discovery, development and
commercialization of proprietary disease-specific diagnostic agents and
therapeutics for life-threatening conditions. The foundation of Diatide's
diagnostic imaging products is the Company's proprietary peptide (Techtide(R))
technology.
 
2.  BASIS OF PRESENTATION
 
     The accompanying unaudited financial statements for the three and six
months ended June 30, 1997 and 1996 and for the period February 6, 1990 (date of
inception) to June 30, 1997 have been prepared in accordance with generally
accepted accounting principles for interim financial information and with the
instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do
not include all the information and footnotes required by generally accepted
accounting principles for complete financial statements. In the opinion of
management, the accompanying financial statements include all adjustments of a
normal recurring nature necessary for a fair presentation of results for these
interim periods. The results of operations for the three and six months ended
June 30, 1997 are not necessarily indicative of the results to be expected for
the year ending December 31, 1997.
 
     These financial statements should be read in conjunction with the audited
financial statements and notes thereto for the year ended December 31, 1996
included in the Company's Annual Report on Form 10-K for the year ended December
31, 1996.
 
3.  PUBLIC OFFERING
 
     In June 1996, the Company completed its initial public offering of
2,200,000 shares of Common Stock raising approximately $16.4 million of net
proceeds after deducting offering costs. Concurrent with the completion of the
initial public offering, all 12,551,928 shares of Series A, Series B, Series C,
Series D and Series E Convertible Preferred Stock (collectively, the
"Convertible Preferred Stock") were converted into 7,531,140 shares of Common
Stock. In connection with this conversion, all such shares of Convertible
Preferred Stock were retired.
 
4.  FINANCIAL INFORMATION
 
     For 1996, pro forma net loss per share is computed using the weighted
average number of outstanding shares of Common Stock and Common Stock
equivalents and assuming the previously outstanding Convertible Preferred Stock
had been converted into common shares effective at the beginning of the
respective period. Common Stock equivalent shares are excluded from the
computation if their effect is anti-dilutive; however, pursuant to the
requirements of the SEC, common shares issued by the Company and common
equivalent shares relating to stock options (using the treasury stock method)
issued during the twelve months prior to the initial public offering are
included whether or not they are anti-dilutive. Historical earnings per share
have not been presented for the six months ended June 30, 1996 since such
amounts are not deemed meaningful due to the significant change in the Company's
capital structure that occurred in connection with the initial public offering.
For the three and six months ended June 30, 1997, net loss per share is computed
using the weighted average number of outstanding shares of common stock. Common
stock equivalents are excluded from the computation since their effect is
anti-dilutive.
 
     The common share amounts and per share dollar amounts have been adjusted
for all periods presented to reflect the effect of the 6-for-10 reverse stock
split effective June 6, 1996.
 
     In February 1997, the Financial Accounting Standards Board issued Statement
No. 128, Earnings per Share (FAS No. 128), which is required to be adopted for
fiscal years ending after December 15, 1997. At
 
                                        7
<PAGE>   8
 
that time, the Company will be required to change the method currently used to
compute earnings per share and to restate all prior periods. Under FAS No. 128,
the dilutive effect of stock options will be excluded in calculating earnings
per share. There is no material impact on the net loss or proforma net loss per
share for the three and six months ended June 30, 1997 and 1996 under FAS No.
128.
 
ITEM 2.  MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS
OF OPERATIONS
 
     The Company is engaged in the discovery, development and commercialization
of proprietary, disease-specific diagnostic agents and therapeutics for
life-threatening conditions. The foundation of Diatide's diagnostic imaging
products is the Company's proprietary peptide (Techtide(R)) technology. To date,
the Company has not received revenue from the sale of products. In order to
commercialize products, the Company will need to address a number of
technological challenges and comply with comprehensive regulatory requirements.
Accordingly, it is not possible to predict the amount of funds that will be
required or the length of time that will pass before the Company receives
revenues from sales of its products. All revenues received by the Company
through June 30, 1997 have resulted from research grants from the National
Institutes of Health (the "NIH") and the Department of Defense (collectively,
the "Research Grants"), fees received for entering into option agreements with a
pharmaceutical company, and research and development support payments and the
P280 and the P829 option exercise payments from Nycomed ASA ("Nycomed") under
the Company's collaborative agreements with Nycomed.
 
     The Company has incurred net losses since its inception. No revenues have
been generated from product sales and no product sales are anticipated for the
next 12 to 18 months. The Company expects to incur additional significant
operating losses over the next 18 to 30 months and expects its cumulative net
losses to increase significantly as the Company's research and development and
clinical trial efforts expand. The Company expects that its personnel and patent
costs will increase in the future. Patent costs also would increase if the
Company became involved in litigation or administrative proceedings involving
its patents or those of third parties. The Company has incurred cumulative net
losses since inception through June 30, 1997 of $40,246,034.
 
     This Quarterly Report on Form 10-Q contains forward-looking statements that
involve a number of risks and uncertainties. There are a number of important
factors that could cause the Company's actual results to differ materially from
those indicated by such forward-looking statements. These factors include,
without limitation, those set forth in "Item 7. Management's Discussion and
Analysis of Financial Condition and Results of Operations -- Certain Factors
That May Affect Future Results" of the Company's Annual Report on Form 10-K as
of December 31, 1996, which are expressly incorporated by reference herein.
 
RESULTS OF OPERATIONS
 
  THREE MONTHS ENDED JUNE 30, 1997 AND 1996
 
     Revenues.  The Company had revenues of $530,000 and $1,056,073 in the three
months ended June 30, 1997 and 1996, respectively. Revenues in the three months
ended June 30, 1997 were comprised of $30,000 of contract revenues received
under research grants from the NIH, and $500,000 of research and development
support payments received by the Company under its collaborative agreements with
Nycomed. Revenues in the three months ended June 30, 1996 were comprised of
$56,073 received under research grants from the NIH, and $500,000 of research
and development support payments and a $500,000 option exercise payment for P829
received by the Company under its collaborative agreements with Nycomed.
 
     Research and development.  During the three months ended June 30, 1997 and
1996, the Company expended $3,219,125 and $3,663,644, respectively, on research
and development activities. The $444,519 decrease in the three months ended June
30, 1997 in comparison with the same period in 1996 resulted from reduced
expenses associated with the timing of initial costs for clinical trials.
 
     General and administrative.  The Company's general and administrative
expenses were $862,302 and $584,588 in the three months ended June 30, 1997 and
1996, respectively. The $277,714 increase in 1997 from 1996 resulted from
increases in staffing and outside services to support the Company's growth.
 
                                        8
<PAGE>   9
 
     Interest.  Interest income was $182,423 in the three months ended June 30,
1997 compared with $108,368 in the three months ended June 30, 1996, reflecting
an increase in the Company's cash, cash equivalents and marketable securities
resulting from the proceeds of the Company's initial public stock offering in
June 1996. Interest expense in the three months ended June 30, 1997 and 1996 was
$452 and $6,142, respectively, and was comprised primarily of interest incurred
on borrowings to finance the acquisition of certain equipment and leasehold
improvements. During the third quarter of 1996, the Company repaid its bank
borrowings.
 
     Net loss. As a result of the above factors, the Company incurred net losses
of $3,369,456 and $3,089,933 in the three months ended June 30, 1997 and 1996,
respectively.
 
  SIX MONTHS ENDED JUNE 30, 1997 AND 1996
 
     Revenues.  The Company had revenues of $1,110,000 and $1,556,073 in the six
months ended June 30, 1997 and 1996, respectively. Revenues in the six months
ended June 30, 1997 were comprised of $110,000 of contract revenues received
under grants from the NIH and $1,000,000 of research and development support
payments received by the Company under its collaborative agreements with
Nycomed. Revenues in the six months ended June 30, 1996 were comprised of
$56,073 of contract revenues received under research grants from the NIH, and
$1,000,000 of research and development support payments and a $500,000 option
exercise payment for P829 received by the Company under its collaborative
agreements with Nycomed.
 
     Research and development.  During the six months ended June 30, 1997 and
1996, the Company expended $5,990,007 and $6,192,247, respectively, on research
and development activities. The $202,240 decrease in the six months ended June
30, 1997 resulted from reduced expenditures associated with the timing of
initial costs for clinical trials in the second quarter of 1997.
 
     General and administrative.  The Company's general and administrative
expenses were $1,581,443 and $1,023,600 in the six months ended June 30, 1997
and 1996, respectively. The $557,843 increase in the six months ended June 30,
1997 resulted from increases in staffing and outside services to support the
Company's growth.
 
     Interest.  Interest income was $397,638 in the six months ended June 30,
1997 compared with $224,757 in the six months ended June 30, 1996, reflecting
the Company's increased cash, cash equivalents and marketable securities during
1997 resulting from the proceeds of the Company's initial public stock offering.
Interest expense in the six months ended June 30, 1997 and 1996 was $957 and
$16,176, respectively, and was comprised primarily of interest incurred on
borrowings to finance the acquisition of certain equipment and leasehold
improvements. During the third quarter of 1996, the Company repaid its bank
borrowings.
 
     Net loss.  As a result of the above factors, the Company incurred net
losses of $6,064,769 and $5,451,193 in the six months ended June 30, 1997 and
1996, respectively.
 
  LIQUIDITY AND CAPITAL RESOURCES
 
     The Company completed its initial public offering of 2,200,000 shares of
Common Stock in June 1996 raising approximately $16.4 million of net proceeds.
As of June 30, 1997, the Company had $10,476,236 of cash, cash equivalents and
marketable securities and working capital of $7,987,166.
 
     During the six months ended June 30, 1997, the Company's capital
expenditures totaled $140,855, primarily for the acquisition of certain
equipment and furniture and fixtures.
 
     The Company's future capital requirements will depend on many factors,
including continued progress in its research and product development programs,
the magnitude of these programs, the results of preclinical studies and clinical
trials, the time and costs involved in obtaining regulatory approvals, the costs
involved in filing, prosecuting, enforcing and defending patent claims,
competing technological and market developments, the ability of the Company to
establish and maintain collaborative academic and commercial research,
development and marketing relationships, and the costs and success of
commercialization activities and arrangements.
 
                                        9
<PAGE>   10
 
     Based on its current operating plan, the Company anticipates that its
existing capital resources, including the proceeds of the initial public
offering and interest earned thereon, will be adequate to satisfy its capital
requirements through mid-1998. Substantial additional funds will be required
from external sources to support the Company's operations beyond that time,
although there can be no assurance that additional funds will be available, or,
if available, that such funds will be available on acceptable terms.
 
     The Company intends to seek additional equity, debt and lease financing to
fund future operations, depending upon the terms on which such sources may be
available from time to time. In addition, the Company intends to seek additional
collaborative development and commercialization relationships with potential
corporate partners in order to fund certain of its programs, including the
continued development and commercialization of Sn-117 DTPA.
 
     Except for research and development funding from Nycomed pursuant to its
collaboration with Diatide (which is subject to early termination in certain
circumstances), the Company has no committed external sources of capital, and,
as discussed above, expects no product revenues for a number of years. If the
Company is unable to obtain necessary additional funds, it would be required to
delay, scale back or eliminate certain of its research and development programs
or commercialization efforts or license to third parties certain technologies
which the Company would otherwise pursue on its own.
 
                                       10
<PAGE>   11
 
                                    PART II.
 
                               OTHER INFORMATION
 
ITEM 4.  SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS
 
     At the Company's Annual Meeting of Stockholders held on May 21, 1997, the
following proposals were adopted by the vote specified below:
 
     (a) Election of Class I Directors
 
<TABLE>
<CAPTION>
                                      FOR          WITHHELD AUTHORITY
                                      ---          ------------------
        <S>                        <C>                   <C>
        Gustav Christensen         6,302,074             1,530
        Hirsch Handmaker, MD       6,302,024             1,580
        Donald L. Murfin           6,302,074             1,530
</TABLE>
 
     (b) Ratification of Selection of Independent Auditors
 
<TABLE>
<CAPTION>
           FOR        AGAINST     ABSTAIN     BROKER NON-VOTES
           ---        -------     -------     ----------------
        <S>            <C>         <C>              <C>       
        6,302,604      1,000        --               --
</TABLE>
 
ITEM 6.  EXHIBITS AND REPORTS ON FORM 8-K:
 
     (a) Exhibits.
         The Exhibits listed in the Exhibit Index immediately preceding such
         Exhibits are filed as part of this Quarterly Report on Form 10-Q.
 
     (b) Reports on Form 8-K.
         None.
 
                                       11
<PAGE>   12
 
                                 DIATIDE, INC.
                                   FORM 10-Q
                                 JUNE 30, 1997
 
                                   SIGNATURES
 
     Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.
 



                                            DIATIDE, INC.
 
DATE: August 13, 1997
                                                    
                                            By:  /s/  DANIEL F. HARRINGTON
                                            ------------------------------------
                                                     Daniel F. Harrington
                                               Vice President, Chief Financial
                                                     Officer and Treasurer
                                                (Principal Financial Officer)
 
                                       12